{"id":"W2898717093","doi":"10.1001/jamaoncol.2018.4628","title":"Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Tremelimumab; Durvalumab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Immunotherapy; Adverse effect; Cancer; Head and neck cancer; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00118837,0.0004538978,0.00120622,0.0001974959,0.0002477558,0.0004460816,0.0004342166,0.0005069992,0.001416892],"category_scores_gemma":[0.00116133,0.0002802403,0.0009232699,0.0002266229,0.0004462769,0.0005038958,0.0001492508,0.001085026,0.0003083246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008998369,"about_ca_system_score_gemma":0.001165248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008918674,"about_ca_topic_score_gemma":0.003578539,"domain_scores_codex":[0.9995546,0.0002112347,0.00003609363,0.00007247522,0.00005999789,0.00006550425],"domain_scores_gemma":[0.999443,0.0001436519,0.0001615943,0.00004710465,0.00003262069,0.0001720696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7706699,0.01353382,0.02620109,0.0007458853,0.001565694,0.0002612752,0.0001588802,0.001933313,0.03365868,0.0001855456,0.002360218,0.1487258],"study_design_scores_gemma":[0.3610873,0.5363356,0.0810749,0.0001019228,0.002405458,0.0008453731,0.0001074217,0.003831896,0.01009388,0.0001737177,0.003891239,0.00005130636],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975138,0.001272641,0.0001014945,0.00009548762,0.0000330611,0.0001438303,0.0001805647,0.00002054489,0.0006386145],"genre_scores_gemma":[0.9985273,0.0004280388,0.0002499957,0.0001077758,0.00005205348,0.0001133916,0.0002205394,0.000003560017,0.000297313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001416892,"threshold_uncertainty_score":0.006528795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02132207823139834,"score_gpt":0.3195066670134031,"score_spread":0.2981845887820048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}